|
|
 |
|
|
 |
Partners
Contained within these pages are the realized hopes and dreams of millions of Americans affected by rare diseases. A Decade of Innovation doesn't just describe a period of stunning medical advances, it documents a brief window in time during which people without hope learned to believe again that they might have a future. This book tells the stories of numerous individuals and the remarkable legislation—the Orphan Drug Act of 1983—that has given them back their lives. The National Organization for Rare Disorders (NORD) is grateful to PhRMA for focusing this spotlight on rare diseases. We look forward to continued partnership with all those involved in the rapidly unfolding drama of bringing safe and effective new treat-ments to market for the 25 million Americans with rare diseases.
Abbey S. Meyers, President, NORD
Carolyn Asbury, Ph.D., Chairman, Board of Directors, NORD
For more information about NORD, visit http://www.rarediseases.org/.
Genetic Alliance applauds these advances in treating rare diseases. We are grateful that the continuum of basic science to medical services is infused with the time, energy, and resources of many talented individuals, particularly those who are part of the member companies of PhRMA. Genetic Alliance members, 600 disease advocacy organizations, representing over 1,000 diseases, look forward to the day they too will celebrate a treatment. Meanwhile, we stand beside you in gratitude and support your marvelous accomplishments.
Sharon F. Terry, President and CEO, Genetic Alliance
For more information about Genetic Alliance, visit http://geneticalliance.org/.
|
|
